Treatment of Subclinical Hypothyroidism Reduces Atherogenic Lipid Levels in a Placebo-controlled Double-blind Clinical Trial

Abstract

Many studies have found clinical and metabolic alterations in subclinical hypothyroidism, however, there are disagreements about the benefits of levothyroxine therapy. The objective of the present study was to analyze the effects of 6 months of treatment on the lipid profile of patients with subclinical hypothyroidism. A randomized double blind, placebo-controlled clinical assay was conducted. Sixty patients were enrolled in stratified random allocation by TSH levels that generated similar groups in average: free thyroxine levels, lipid levels, age, clinical score, and sedentary. At 6 months, 18 patients in the levothyroxine and 20 in the placebo group were reevaluated and a fall in all atherogenic lipid variables was observed with treatment. The TC and LDL-c variations (-22.6±37.2 and -18.5±34.6 mg/dl, respectively) in the group that received LT4 were statistically different (p=0.023 and p=0.012) from those occurring in the placebo group (+7.3±37.1 and +14.7±40.6 mg/dl). Baseline characteristics associated with better improvement in the levels of TC and LDL-c were the presence of TPO-Ab, TSH levels >8.0 μUI/ml, Body Mass Index ≥25 kg/m², and the presence of menopause. We concluded that treatment with dose-adjusted levothyroxine reduced atherogenic lipid levels in some patients. Further studies to determine the effects of LT4 replacement in specific subgroups of SH patients are still necessary, especially in patients with TSH <8.0 μUI/ml.

Key words

subclinical hypothyroidism - lipid - cholesterol - clinical trial - thyroid - levothyroxine

References

• 1 Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershmam JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical Thyroid Disease. Scientific review and guidelines for diagnosis and management.  JAMA. 2004;  291 228-238
• 2 Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T4 and thyroid antibodies in the United States population (1988-1994): National Health and Nutrition Examination Survey (NHANES III).  J Clin Endocrinol Metab. 2002;  87 489-499
• 3 Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA. Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure.  Clinical Endocrinol (Oxf). 1977;  7 495-508
• 4 Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study.  Arch Intern Med. 2000;  160 526-534
• 5 Cabral MD, Costa A J L, Santos MC F, Vaisman M. Lipid profile in subclinical hypothyroidism.  Endocrinologist. 2004;  14 121-125
• 6 Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study.  Ann Intern Med. 2003;  132 270-278
• 7 Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism.  JAMA. 2005;  294 71-80
• 8 Chu JW, Capro LM. Clinical perspective. The treatment of subclinical hypothyroidism is seldom necessary.  J Clin Endocrinol Metab. 2001;  86 4591-4599
• 9 Michalopoulou G, Alevizaki M, Piperingos G, Mitsibounas D, Mantzos E, Adamapoulos P, Koutras DA. High serum cholesterol levels in persons with ‘high-normal’ TSH levels: should one extend the definition of subclinical hypothyroidism?.  Eur J Endocrinol. 1998;  138 141-145
• 10 Duntas LH. Thyroid disease and lipids.  Thyroid. 2002;  2 287-293
• 11 Danese MD, Ladenson P W, Meinert CL, Powe N R. Clinical review 115: Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: A quantitative review of the literature.  J Clin Endocrinol Metab. 2000;  85 2993-3001
• 12 Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. l-thyroxine therapy in subclinical hypothyroidism.  Ann Intern Med. 1984;  101 18-24
• 13 Nystrom E, Caidahl K, Fager G, Kikkelso C, Lundberg PA, Lindstedt G. A double-bind cross-over 12-month study of l-thyroxine treatment of women with subclinical hypothyroidism.  Clin Endocrinol (Oxf). 1988;  29 63-76
• 14 Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B. TSH-controlled l-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: A double-bind placebo-controlled trial (Basel Thyroid Study).  J Clin Endocrinol Metab. 2001;  86 4860-4866
• 15 Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: Response to levothyroxine replacement, a randomized placebo-controlled study.  J Clin Endocrinol Metab. 2002;  87 1533-1538
• 16 Monzani F, Caraccio N, Kozakowa M, Dardano A, Vittone F, Virdis A, Taddei S, Palombo C, Ferranini E. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study.  J Clin Endocrinol Metab. 2004;  89 2099-2106
• 17 Zulewski H, Muller B, Exer P, Miserez AR, Staub JJ. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls.  J Clin Endocrinol Metab. 1997;  82 771-776
• 18 National Cholesterol Education Program (U.S.) .Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Bethesda: National Cholesterol Education Program, National Heart, Lung, and Blood Institutes, National Institutes of Health 2002: 336
• 19 Ozata M, Yildirimkaya M, Yilmaz K, Kutluay T, Corakci A, Beyhan Z, Gundogan MA. The effects of thyroid status on serum apolipoprotein A-I containing lipoprotein particles.  Horm Metab Res. 1998;  30 217-221
• 20 Milionis HJ, Efstahiadou Z, Tselepis AD, Bairakitari ET, Tsironis LD, Tsatsoulis A, Lisaf MS. Lipoprotein (a) levels and apoprotein (a) in patients with subclinical hypothyroidism: Effect of treatment with levothyroxine.  Thyroid. 2005;  15 455-460
• 21 Ganotakis ES, Mandalaki K, Tampakaki M, Malliaraki N, Mandalakis E, Vrentzos G, Melissas J, Castanas E. Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: Effect of thyroid replacement therapy.  Angiology. 2003;  54 569-574
• 22 Efstathiadou Z, Bitsis S, Milionis HJ, Kukuvits A, Bairaktari ET, Elisaf MS, Tsatsoulis A. Lipid profile in subclinical hypothyroidism: is l-thyroxine substitution beneficial?.  Eur J Endocrinol. 2001;  145 705-710
• 23 Tsimihodimos V, Bairaktak E, Tzallas C, Miltiadus G, Liberopoulos E, Elisaf M. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic.  Thyroid. 1999;  9 365-368
• 24 Kong WM, Sheikh MH, Lumb PJ, Naoumova RP, Freedman DB, Crook M, Dore CJ, Finer N. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism.  Am J Med. 2002;  112 348-354
• 25 Rosenthal MJ, Hunt WC, Garry PJ, Goodwin JS. Thyroid failure in the elderly: microsomal antibodies as discriminant for therapy.  JAMA. 2002;  258 209-213
• 26 Vanderpump MP, Tunbridge WM. Epidemiology and prevention of clinical and subclinical hypothyroidism.  Thyroid. 2002;  12 839-847
• 27 Kabadi UM. Subclinical hypothyroidism. Natural course of the syndrome during a prolonged follow-up study.  Arch Intern Med. 1993;  153 957-961

Correspondence